So far, nephrologists may exhibit reluctance toward SGLT2 inhibitors due to concerns about their potential impact on hemodynamic, low glucose-lowering efficacy with low glomerular filtration rate, and the potential risk of genito-urinary tract infections. This evidence concerns the gene SLC5A2 and urinary tract infection.